ProKidney (NASDAQ:PROK) Coverage Initiated at Guggenheim
Guggenheim started coverage on shares of ProKidney (NASDAQ:PROK – Free Report) in a research report released on Tuesday, MarketBeat.com reports. The firm issued a buy rating and a $6.00 target price on the stock. Several other research firms have also weighed in on PROK. Bank of America lowered their target price on ProKidney from $4.00 […]
More Stories
The World Looks Upside Down…But It Isn’t
By Louis Navellier The world seems to have been turned upside down, and we are suddenly all living in “Opposite...
US Oil Prices Fall More Than 7 Percent on Iran Peace Talks
By Andrew Moran Crude oil prices fell sharply to start the trading week on hopes of peace talks with Iran....
Appeals Court Allows Trump Admin Effort Targeting Noncitizen Voting
By Zachary Stieber A federal appeals court on Nov. 3 reinstated a decision that stays a restraining order that had...
US Manufacturing Expands for 10th Straight Month Amid High Input Costs
By Bill Pan U.S. manufacturing activity strengthened in October as new orders increased, although raw materials became more expensive and...
America Votes: What to Expect
By Lawrence Wilson Democrats appear poised to win control of the House and possibly the Senate on Nov. 3 as...
One Canadian Confirmed Among 69 Victims of Fatal Spanish Train Crash
By Jennifer Cowen Global Affairs has confirmed one Canadian was killed in last week’s high-speed rail collision in Spain. Sixty-nine...
